![UMN logo](/assets/logo-14ca9c5bc764343ea0b1ec3edef3d39b15c438f8eb603b1a5fbf826128a74246.png)
StudyFinder
MT2021-08: Phase II, Open-Label, Prospective Study of T Cell Receptor Alpha/Beta Depletion (A/B TCD) Peripheral Blood Stem Cell (PBSC) Transplantation for Children and Adults with Hematological Malignancies
![](/assets/flag-998f631fa7bef54098575ae881e66e71315bfae4a5d1ffb34ab8f527fcff0600.jpg)
Recruiting
The research aspect of this trial is the use of a new machine to remove specific lymphocytes from the donor’s peripheral blood stem cells (PBSCs). This is called T cell receptor alpha/beta T cell depletion. This machine does such a good job at removing the unwanted donor T cells, and as a result we think patients will need fewer drugs to suppress their immune system.
Male or Female
Not specified
Inclusion Criteria:
• hematological cancer needing stem cell transplant
• 60 years old or younger
Exclusion Criteria:
• pregnant or breast feeding
• active infection
• positive for HIV, Hepatitis B or C
• brain metastasis
Cancer
Hematologic Malignancy, Leukemia, Stem Cell Transplant, Clinics and Surgery Center (CSC)
Andrea Middendorf - midde019@umn.edu
Margaret MacMillan, MD
STUDY00016450
See this study on ClinicalTrials.gov